Citalopram Hydrochloride

A new study compared weight change across eight common first-line antidepressants for patients taking an antidepressant for the first time. The study found differences in weight change between the different antidepressants after medication initiation, with bupropion consistently showing the least weight gain. The study adds rigorous evidence on expected weight gain across common antidepressant treatments. New evidence comparing weight gain under eight different first-line antidepressants finds that bupropion users are 15-20% less likely to gain a clinically significant amount of weight than users of sertraline, the most common medication. The findings are published July 2 in Annals of Internal Medicine. Antidepressants are among the most commonly prescribed medications in the U.S., with 14% of U.S. adults reporting using an antidepressant. Weight gain is a common side effect, which could affect patients' long-term metabolic health and cause some to stop taking their prescribed treatment, leading to poor clinical outcomes. Although antidepressants overall are associated with weight gain, specific antidepressant medications may affect weight differently. The new findings, led by investigators from the Harvard Pilgrim Health Care Institute reveal which common antidepressants are associated with the most and least weight gain following medication initiation. "Patients and their clinicians often have several options when starting an antidepressant for the first time. This study provides important real-world evidence regarding the amount of weight gain that should be expected after starting some of the most common antidepressants," said lead author Joshua Petimar, Harvard Medical School assistant professor of population medicine at the Harvard Pilgrim Health Care Institute. "Clinicians and patients can use this information, among other factors, to help decide on the right choice for them." Researchers used electronic health record prescription data from eight health systems in the U.S. participating in PCORnet, the National Patient-Centered Clinical Research Network, to conduct the study using data from 183,118 adults ages 18-80 years who were new users of antidepressants. While randomized control trials are considered the most rigorous method for comparing the effects of different medications, they are prohibitively costly and time consuming. In this case, the study team emulated a randomized trial by designing their ideal, hypothetical trial and aligning the data to match that trial as closely as possible. Study investigators compared weight at 6, 12, and 24 months after initiation of eight common antidepressants: sertraline, citalopram, escitalopram, fluoxetine, paroxetine, bupropion, duloxetine, and venlafaxine. Results showed that bupropion users gained the least amount of weight compared to users of other antidepressants. Bupropion users were approximately 15-20% less likely to gain a clinically significant amount of weight than those taking the most common medication, sertraline. The researchers considered weight gain of 5% or more as clinically significant. Results also showed a large percentage of patients were taking a medication that led to greater weight gain than alternatives that are commonly available in the same class or subclass. For example, sertraline, escitalopram, and paroxetine are all selective serotonin reuptake inhibitors (SSRI), the most common type of antidepressant, but escitalopram and paroxetine were each associated with an approximate 15% higher risk of gaining a clinically significant amount of weight than sertraline in the first 6 months. "Although there are several reasons why patients and their clinicians might choose one antidepressant over another, weight gain is an important side effect that often leads to patients stopping their medication," said senior author Jason Block, a general internal medicine physician and Harvard Medical School associate professor of population medicine at the Harvard Pilgrim Health Care Institute. "Our study found that some antidepressants, like bupropion, are associated with less weight gain than others. Patients and their clinicians could consider weight gain as one reason for choosing a medication that best fits their needs."

ANT-01 is in late-stage development as an adjunctive treatment for major depressive disorder (MDD), with minimal side effects Published data demonstrates substantially better safety profile of ANT-01 than previous serotonin and dopamine antagonists for the treatment of MDD ANeuroTech also files patent application for long-acting prodrugs 31 January 2024: ANeuroTech, a leader in the development of innovative mental health treatments with minimal or no side effects, today announced the publication of Phase IIIa data for ANT-01, its adjunctive anti-depression drug, in the journal of Personalized Medicine in Psychiatry. The Company also filed a Composition of Matter (CoM) patent for the long-acting effects of ANT-01. The Phase IIIa data, published in a paper titled: Low dose pipamperone therapy for major depression: A randomized controlled clinical trial comparison with citalopram, demonstrates that ANT-01 has a substantially better safety profile than previous serotonin and dopamine antagonists used to treat MDD, and that low dose pipamperone has the potential to be an efficacious treatment for MDD as either a monotherapy or in combination with currently available anti-depressants. The paper was co-authored by Erik Buntinx, Lars Bastiaanse, Alan S Schatzberg, Charles B Nemeroff and Philip D Harvey. ANT-01 is a highly selective dopamine and serotonin receptor antagonist and a low dose of an existing drug substance, pipamperone dihydrochloride, a typical antipsychotic developed and marketed at a high dose range for the treatment of psychotic disorders. ANT-01 has been shown to improve cognitive function and anhedonia, something which has not been demonstrated by any other adjunctive antidepressant molecule, with data demonstrating it is more efficient, with an improved safety profile, when compared with currently available adjunctive therapies. ANeuroTech is also developing prodrugs of ANT-01 as a long-acting treatment for MDD. Long-acting treatments remove the need for daily medication, resulting in better patient adherence and a better patient experience. There is currently no long-acting anti-depressant drug available. Dr Erik Buntinx, CEO and Founder of ANeuroTech, commented: “As a psychiatrist, I have seen too often the non-response and problems that come with adjunctive anti-depressant drugs, including a lack of an effective impact on cognitive dysfunctioning and on the loss of the ability to feel pleasure, two key domains in almost all MDD patients with an inadequate response on their initial antidepressant. At ANeuroTech, we are working to bring effective treatments, with minimal or no side-effects, to patients who suffer with depression. The publication in Personalized Medicine in Psychiatry and our patent filing for a long-acting drug are two important milestones in our efforts to meet our goal of finding better ways to help people with MDD.” ANeuroTech, based in Alken, Belgium, is a leader in the development of innovative mental health treatments with minimal or no side effects. The company is in late-stage clinical development of its lead asset, ANT-01, an adjunctive anti-depression drug which has been shown in late-stage clinical trials to improve depression and have a positive impact on cognitive function and anhedonia, with an excellent safety profile. ANT-01 is a low-dose of an existing drug substance, pipamperone dihydrochloride, a typical antipsychotic discovered by the late Dr Paul Janssen and marketed in Europe for the treatment of psychotic disorders. ANeuroTech plans to begin a pivotal Phase IIIb clinical trial of ANT-01 as an adjunctive anti-depression drug for major depressive disorder (MDD) in 2024. ANeuroTech was founded by CEO, Dr Erik Buntinx, an experienced clinician, key opinion leader and global coordinating principal investigator on clinical trials for a number of CNS drugs including Spravato (esketamine). Many of the ANeuroTech team were previously at Johnson & Johnson where they gained extensive experience in the development of treatments for mental and other health disorders. For more information, please visit: https://www.aneurotech.com/ The content above comes from the network. if any infringement, please contact us to modify.